BackgroundAsthma is one of the most common chronic respiratory conditions worldwide. Asthma-related economic burden has been reported in Latin America, but knowledge about its economic impact to the Colombian health care system and the influence of disease severity is lacking. This study estimated direct medical costs and health care resource utilization (HCRU) in patients with asthma according to severity in Colombia.MethodsThis study identified all-age patients who had at least one medical event linked to an asthma diagnosis (CIE-10: J45-J46) between 2004 and 2014. Patients were selected if they had a continuous enrollment and uninterrupted insurance coverage between January 1–2015 and December 31–2015 and were categorized into 4 different severity levels using a modified algorithm based on Leidy criteria. Healthcare utilization and costs were estimated in a 1-year period after the identification period. A Generalized Linear Model (GLM) with gamma distribution and log link was used to analyze costs adjusting for patient demographics.ResultsA total of 20,410 patients were included: 69.5% had mild intermittent, 18.0% mild persistent, 6.9% moderate persistent and 5.5% severe persistent asthma; with mean costs (SD) of $67 (134), $482 (1506), $1061 (1983), $2235 (3426) respectively (p < 0.001). The mean total direct cost was estimated at $331 (1278) per patient. Medication and hospitalization had the higher proportion in total costs (46% and 31% respectively). General physician visits was the most used service (57.2%) and short-acting β-2 agonists the most used medication (24%).ConclusionsHealth services utilization and direct costs of asthma were highly related to disease severity. Nationwide health policies aimed at the effective control of asthma are necessary and would play an important role in reducing the associated economic impact.Electronic supplementary materialThe online version of this article (10.1186/s40413-018-0205-4) contains supplementary material, which is available to authorized users.
and 41.9 respectively. SF-36 bodily pain, social functioning, and emotional domain mean scores were 57.5, 62.9, and 63.2 respectively. Of the PSC cohort, 57% (n= 157) reported that SpA has been or currently is a major problem in their life, and 74% (n= 204) were concerned about possible medication side-effects. ConClusions: This analysis shows that SpA represents a considerable burden to both patients and society overall in Mexico and Brazil. It further highlights the need for effective therapies to control both peripheral and axial Spondyloarthritis.
is a modality of renal replacement therapy that depends on a viable vascular access. The temporary double-lumen catheter (TBLC) provides immediate management; however, its use implies complications. This research aimed to calculate the average cost of TBLC use in chronic renal failure patients undergoing HD. Methods: It was an observational cost assessment study, with quantitative approach, performed in the HD unit of a University Hospital in Rio de Janeiro, Brazil in the period from April to September 2015. The sample consisted of 20 patients using TBLC who started dialysis. Data were analyzed using the statistical program Epi Info and Excel® 2010. Ethics Committee approved the study with
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.